Odevixibat demonstrates continued and durable reductions in serum bile acids in patients with progressive familial intrahepatic cholestasis (PFIC) in open-label Phase III extension study

Long-term data from PEDFIC 2, also showed improvement in pruritus assessments and markers of liver and growth function in patients treated up to 48 weeks with odevixibat, an oral inhibitor of the ileal bile acid transporter. New Drug Application to FDA planned first quarter 2021.

Source:

Biospace Inc.